InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19

• InflaRx N.V. (NASDAQ: IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.

• The FDA and the European Medicines Agency (EMA) have granted orphan drug designation to vilobelimab for PG.

• PG is a rare condition that causes large, painful sores (ulcers) to develop on the skin.

• In addition, the company had a productive FDA end-of-phase II meeting to its plans for a Phase 3 development program in PG.

• The FDA indicated its support for a randomized, controlled Phase 3 study and offered to review the study protocol.

• Based on the agency's feedback and recommendations, InflaRx is now finalizing the design for a Phase 3 trial.

• InflaRx requested a meeting with the FDA to obtain guidance for a potential emergency use authorization submission of vilobelimab in COVID-19 patients.

• Related: InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients.

• This has been scheduled as a Type B meeting for early Q3. In addition, the company is in ongoing dialogue with the EMA about the next steps in developing vilobelimab in mechanically ventilated severe COVID-19 patients.

• Price Action: IFRX shares were down 6.91% at $1.42 during the market session on the last check Wednesday.

See more from Benzinga

• Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

• Why Patterson Companies Shares Are Surging Today

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.